Cite
MLA Citation
B. Vormoor et al.. “A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.” Pediatric blood & cancer, vol. 64, no. 6, 2017, p. n/a. http://access.bl.uk/ark:/81055/vdc_100045916217.0x000033